Signal Analysis of Niraparib-Related Adverse Events Based on US FAERS Database

Hongying XIA; Wenjie YIN; Yanhua LI; Lina YOU; Xingxing Geng; Feilong TAN

doi:10.12259/j.issn.2095-610X.S20250217

Volume 46 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2025 > 46(2): 118-125

Hongying XIA, Wenjie YIN, Yanhua LI, Lina YOU, Xingxing Geng, Feilong TAN. Signal Analysis of Niraparib-Related Adverse Events Based on US FAERS Database[J]. Journal of Kunming Medical University, 2025, 46(2): 118-125. doi: 10.12259/j.issn.2095-610X.S20250217

Citation:

Hongying XIA, Wenjie YIN, Yanhua LI, Lina YOU, Xingxing Geng, Feilong TAN. Signal Analysis of Niraparib-Related Adverse Events Based on US FAERS Database[J]. Journal of Kunming Medical University, 2025, 46(2): 118-125. doi: 10.12259/j.issn.2095-610X.S20250217

Citation:

PDF( 2004 KB)

Signal Analysis of Niraparib-Related Adverse Events Based on US FAERS Database

doi: 10.12259/j.issn.2095-610X.S20250217

1.
Department of Pharmacy，Yan’an Hospital Affiliated to Kunming Medical University，Kunming Yunnan 650051
2.
Department of Pharmacy，The Second People’s Hospital of Qujing，Qujing Yunnan 655400，China

Received Date: 2024-09-14
Available Online: 2025-01-04
Publish Date: 2025-02-18

Abstract

Abstract

Objective To explore the risk signals of niraparib and provide references for rational and safe clinical medication. Methods Niraparib-related adverse drug events （ADEs） reports from Q1 2017 to Q2 2023 were extracted from the US FDA Adverse Event Reporting System （FAERS） database. Risk signals were identified using the reporting odds ratio （ROR）, proportional reporting ratio （PRR）, Bayesian confidence propagation neural network （BCPNN）, and multi-item gamma Poisson shrinker （MGPS） methods. The Risk signals were described and classified by preferred system organ classes （SOCs） and preferred terms （PTs） from the Medical Dictionary for Regulatory Activities （MedDRA） version 26.1, and the occurrence of niraparib-related ADEs was also analyzed. Results A total of 16,961 ADE reports with niraparib as the primary suspected drug were extracted. Through screening and analysis, 32 PTs were identified involving 11 SOCs, which were largely consistent with the information in the drug label. However, suspicious signals not mentioned in the label, including neuropathy peripheral, decreased red blood cell count, reduced hematocrit, dehydration, and hot flashes, require further attention.The median occurrence time was 22 days （IQR 2-98 days）, and the Weibull distribution test indicated an early failure-type curve. Conclusion When using niraparib, particularly in early stages of treatment, it is essential to monitor not only the ADEs mentioned in the drug instructions, such as decreased platelet count, nausea and fatigue, but also to pay close attention to the ADEs not included in the instructions, such as peripheral neuropathy and decreased red blood cell count, which exhibit strong signal values, to ensure patient medication safety.
- Niraparib,
- FDA adverse event reporting system,
- Disproportionality measurement,
- Risk signal

FullText(HTML)

References(23)

References

[1]	Maiorano M F P,Maiorano B A,Biancofiore A,et al. Niraparib and advanced ovarian cancer: A beacon in the non-BRCA mutated setting[J]. Pharmaceuticals (Basel),2023,16(9):1261. doi: 10.3390/ph16091261
[2]	Scott L J. Niraparib: First global approval[J]. Drugs,2017,77(9):1029-1034. doi: 10.1007/s40265-017-0752-y
[3]	Del Campo J M,Matulonis U A,Malander S,et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial[J]. J Clin Oncol,2019,37(32):2968-2973. doi: 10.1200/JCO.18.02238
[4]	González-Martín A,Pothuri B,Vergote I,et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med.,2019,381(25):2391-2402. doi: 10.1056/NEJMoa1910962
[5]	英国警示尼拉帕利的严重高血压及可逆性后部脑病综合征风险[J]. 中国药物价,2021,38(2): 152.
[6]	Smith M R,Scher H I,Sandhu S,et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre,open-label,phase 2 trial[J]. Lancet Oncol,2022,23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9
[7]	Jiang Y,Zhou L,Shen Y,et al. Safety assessment of brexpiprazole: Real-world adverse event analysis from the FAERS database[J]. J Affect Disord,2024,346:223-229. doi: 10.1016/j.jad.2023.11.025
[8]	Mao X,Zhang R,Liang X,et al. A pharmacovigilance study of FDA adverse events for sugammadex[J]. J Clin Anesth,2024,97:111509. doi: 10.1016/j.jclinane.2024.111509
[9]	苏小涵,曾姣,李雪,等. 基于美国FAERS数据库的乳腺癌患者使用阿贝西利不良事件分析[J]. 中国药物警戒,2024,21(5):580-586.
[10]	孔北华,刘继红,黄鹤,等. 卵巢癌 PARP 抑制剂临床应用指南(2022版)[J]. 现代妇产科进展,2022,31(8):561-572.
[11]	Hirschl N,Leveque W,Granitto J,et al. PARP inhibitors: Strategic use and optimal management in ovarian cancer[J]. Cancers (Basel),2024,16(5):932. doi: 10.3390/cancers16050932
[12]	Wu X H,Zhu J Q,Yin R T,et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized,double-blind,placebo-controlled phase III trial[J]. Ann Oncol,2021,32(4):512-521. doi: 10.1016/j.annonc.2020.12.018
[13]	Li N,Zhu J,Yin R,et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized,double-blind,placebo-controlled,phase 3 trial (LBA 5)[J]. Gynecologic Oncology,2022,166:S50-S51.
[14]	Liu J F,Gaillard S,Wahner Hendrickson A E,et al. Niraparib,dostarlimab,and bevacizumab as combination therapy in pretreated,advanced platinum-resistant ovarian cancer: Findings from cohort A of the OPAL phase II trial[J]. JCO Precis Oncol,2024,8:e2300693.
[15]	Reiss K A,Mick R,Teitelbaum U,et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: A randomised,phase 1b/2 trial[J]. Lancet Oncol,2022,23(10):e446.
[16]	国家卫生健康委员会办公厅.卵巢癌诊疗指南(2022年版)[EB/OL]. (2022-04-11)[2024-09-02]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml
[17]	Zhao M,Qiu S,Wu X,et al. Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multicenter study in China[J]. Target Oncol,2023,18(6):869-883. doi: 10.1007/s11523-023-00999-x
[18]	刘畅浩,林少丹,林仲秋. 《PARP抑制剂在卵巢癌中的应用: ASCO指南》解读[J]. 中国实用妇科与产科杂志,2020,36(9):835-839.
[19]	Berek J S,Matulonis U A,Peen U,et al. Safety and dose modification for patients receiving niraparib[J]. Ann Oncol,2019,30(5):859. doi: 10.1093/annonc/mdy255
[20]	Jesus M,Cabral A,Monteiro C,et al. Peripheral neuropathy potentially associated to poly (ADP-ribose) polymerase inhibitors: An analysis of the Eudravigilance database[J]. Curr Oncol,2023,30(7):6533-6545. doi: 10.3390/curroncol30070479
[21]	Tian X,Chen L,Gai D,et al. Adverse event profiles of PARP inhibitors: Analysis of spontaneous reports submitted to FAERS[J]. Front Pharmacol,2022,13:851246. doi: 10.3389/fphar.2022.851246
[22]	Balko R A,Hendrickson A W,Grudem M E,et al. Can poly (ADP-ribose) polymerase inhibitors palliate paclitaxel-induced peripheral neuropathy in patients with cancer?[J]. Am J Hosp Palliat Care,2019,36(1):72-75. doi: 10.1177/1049909118786958
[23]	Farr é s J,Llacuna L,Martin-Caballero J,et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors[J]. Cell Death Differ,2015,22(7):1144-1157. doi: 10.1038/cdd.2014.202

Relative Articles(20)

Relative Articles

[1]	Xiaohui GU, Fenrong LV, Ju SUN, Yaping PENG, Dandan WAN. The Effectiveness of Liraglutide Combined with Metformin in Improving Glycolipid Metabolism and Hormonal Levels in Polycystic Ovary Syndrome: A Meta-Analysis. Journal of Kunming Medical University, 2025, 46(3): 1-10.
[2]	Yu CHANG, Li GUI, Ruonan LI. Observation of Liraglutide's Effect on Function of Pancreatic Islets β-Cell in Type 2 Diabetes. Journal of Kunming Medical University, 2025, 46(2): 134-140. doi: 10.12259/j.issn.2095-610X.S20250219
[3]	Qinglan PENG, Jialu LUO, Jiayi YU, Kaixin WANG, Fang WU, Chuanzhi XU. Signal Mining and Analysis of Adverse Events of Azithromycin Based FAERS Database. Journal of Kunming Medical University, 2025, 46(1): 16-22. doi: 10.12259/j.issn.2095-610X.S20250103
[4]	Yiming XU, Jianfeng ZHONG, Bin LI, Xinyan ZHOU, Hongli ZHU, Jing LIANG, Chengde LIAO. Value of Head and Neck 4D-CTA Combined with SDF-1a/CXCR4 Signaling Pathway in Assessing the Risk of Ruptured Intracranial Posterior Communicating Aneurysms. Journal of Kunming Medical University, 2024, 45(3): 59-64. doi: 10.12259/j.issn.2095-610X.S20240309
[5]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[6]	Changji WU, Liu YANG, Xinyu ZHANG. Effects of Paroxetine and Sulpiride in the Treatment of Social Phobia in Young Women and Its Effects on Neurotransmitter and Sleep Structure. Journal of Kunming Medical University, 2023, 44(12): 159-164. doi: 10.12259/j.issn.2095-610X.S20231225
[7]	Liju ZHANG, Xiaoming JIANG, Changxian CHEN, Xi WU, Zhenyong ZHANG, Weijun LIU. Long Non-coding RNA-p21 Regulates the MicroRNA-9 / Sirtuin-1 Signaling Pathway to Reverse Oxaliplatin Resistance in Colorectal Cancer Cells. Journal of Kunming Medical University, 2022, 43(5): 27-32. doi: 10.12259/j.issn.2095-610X.S20220519
[8]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[9]	Zhang Zhi Xian , Gu Hou , Feng Xin Rong , Lin 劼, Lei Xue Fen , Li Nan , Li Rui Zhi , Yu Jia . . Journal of Kunming Medical University, 2020, 41(05): 70-74.
[10]	Gao Qing , Xie Xing , Luo Li . . Journal of Kunming Medical University, 2020, 41(09): 77-81.
[11]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan . . Journal of Kunming Medical University, 2019, 40(02): 123-127.
[12]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Yu Jia . . Journal of Kunming Medical University, 2019, 40(08): 97-101.
[13]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Li Rui Zhi . . Journal of Kunming Medical University, 2019, 40(07): 111-115.
[14]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Li Ting Ting . . Journal of Kunming Medical University, 2018, 39(12): 65-68.
[15]	Lei Jie Peng , Yang Li , Luo Cheng , Zhang Ti Yuan , Lv Xin , Li Sheng Qiao , Lin Hai Bo . Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia. Journal of Kunming Medical University, 2017, 38(09): 92-95.
[16]	Xu Xiao Hong . Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer. Journal of Kunming Medical University,
[17]	Tian Wei . Liraglutide Improves The Symptoms of Non-alcoholic Fatty Liver Disease by Regulating Fatty Acid β-oxidation. Journal of Kunming Medical University,
[18]	Li Xu Hua . . Journal of Kunming Medical University,
[19]	Li Jiang . . Journal of Kunming Medical University,
[20]	. Curative Effects of Integrating Pantoprazole and Mosapride on Gastroesophageal Reflux Disease after Esophagectomy. Journal of Kunming Medical University,